Prab: CSV import

2025-03-17T03:05:06Z

CSV import

← Older revision		Revision as of 03:05, 17 March 2025
Line 32:		Line 32:
	[[Category:Genetic disorders]]		[[Category:Genetic disorders]]
	{{No image}}		{{No image}}
			__NOINDEX__

Prab: CSV import

2025-02-10T05:31:47Z

CSV import

← Older revision		Revision as of 05:31, 10 February 2025
Line 31:		Line 31:
	[[Category:Lipid metabolism]]		[[Category:Lipid metabolism]]
	[[Category:Genetic disorders]]		[[Category:Genetic disorders]]
			{{No image}}

Prab: CSV import

2024-11-28T05:16:43Z

CSV import

New page

== Acid Sphingomyelinase ==

'''Acid sphingomyelinase''' (ASM) is an enzyme that plays a crucial role in the metabolism of sphingolipids, a class of lipids that are important components of cell membranes. ASM is responsible for the hydrolysis of sphingomyelin, a type of sphingolipid, into ceramide and phosphorylcholine. This reaction occurs in the lysosomes, which are organelles involved in the breakdown and recycling of various biomolecules.

=== Function ===
Acid sphingomyelinase is encoded by the ''SMPD1'' gene in humans. The enzyme is active at acidic pH, which is characteristic of the lysosomal environment. The production of ceramide by ASM is significant because ceramide acts as a bioactive lipid mediator involved in various cellular processes, including apoptosis (programmed cell death), cell growth, and differentiation.

=== Clinical Significance ===
Deficiency in acid sphingomyelinase activity leads to the accumulation of sphingomyelin in cells, particularly affecting the liver, spleen, and central nervous system. This deficiency is the underlying cause of [[Niemann-Pick disease]], a group of inherited metabolic disorders. There are two main types of Niemann-Pick disease associated with ASM deficiency:

* '''Type A''': This is the severe infantile form, characterized by rapid neurodegeneration and early death, usually by the age of 3.
* '''Type B''': This is a less severe form, with patients often surviving into adulthood. It primarily affects the liver and spleen, leading to hepatosplenomegaly.

=== Research and Therapeutic Approaches ===
Research into acid sphingomyelinase has led to the development of potential therapies for Niemann-Pick disease. Enzyme replacement therapy (ERT) is one approach, where recombinant human ASM is administered to patients to compensate for the deficient enzyme activity. Gene therapy and substrate reduction therapy are also being explored as potential treatments.

=== Related Enzymes ===
Acid sphingomyelinase is part of a larger family of sphingomyelinases, which also includes neutral sphingomyelinase and alkaline sphingomyelinase. These enzymes differ in their optimal pH and cellular localization.

== Also see ==
* [[Sphingolipid metabolism]]
* [[Ceramide]]
* [[Lysosome]]
* [[Niemann-Pick disease]]
* [[Enzyme replacement therapy]]

{{Enzymes}}
{{Lipid metabolism}}

[[Category:Enzymes]]
[[Category:Lipid metabolism]]
[[Category:Genetic disorders]]

Acid sphingomyelinase - Revision history

Prab: CSV import

Prab: CSV import

Prab: CSV import